A new study published in Bioengineering & Translational Medicine offers an elegant solution inspired by anatomy itself. A research team led by Yi Chieh Chang, Cherng-Shyang Chang, and Chung-Kan Tsao, supported by Chang Gung Memorial Hospital and Taiwan’s National Science and Technology Council, developed a living, bioactive wrapper made from fibroblasts—the connective tissue cells that naturally sheath and support organs. Their insight came from the trachea, the cartilage-ringed windpipe. In the native airway, each cartilaginous ring is enclosed by intercartilaginous ligaments and surrounded by an adventitial layer, a fibrovascular compartment composed largely of fibroblasts that both protects the cartilage and spatially regulates the blood vessels around it. The team hypothesized that recreating this compartment around an implanted cartilage scaffold could tame the chaotic host response.

To build their living interface, the researchers turned to a layer-by-layer assembly technique. Rabbit tracheal fibroblasts, isolated from the fibrovascular compartment of the airway, were repeatedly coated in alternating layers of fibronectin and gelatin, then seeded onto culture dishes over four consecutive days. The coatings allowed the cells to accumulate bottom-up into a dense, cohesive multilayered sheet that, after three additional days of culture, could be peeled off the dish intact, like a delicate living fabric. Three-dimensional confocal microscopy confirmed that fibroblast surface protein and fibronectin were distributed throughout the thickness of the sheet, giving it both structural cohesion and a matrix-rich character reminiscent of natural connective tissue.

But protection alone was not the goal. The team knew that cartilage, being avascular, depends on diffusion from surrounding vascularized tissue for oxygen and nutrients, and that engineered grafts in non-joint sites such as the trachea or the ear require early vascularization to survive. So they incorporated a second cell type: endothelial progenitor cells, or EPCs, isolated from rabbit white adipose tissue. These cells expressed the endothelial marker CD31 and the progenitor marker CD34, and in laboratory assays they formed capillary-like tube structures, confirming their vascular potential. When mixed into the top layer of the fibroblast sheet, the EPCs localized predominantly to the outer surface, creating a spatially organized construct: a fibroblast bulk facing the scaffold and a progenitor-rich vascular layer facing the host.

The testing platform was a polycaprolactone, or PCL, scaffold, a widely used biodegradable polymer known to permit host cell infiltration after implantation—precisely the vulnerability the team wanted to address. The salt-leached, laser-perforated scaffolds were seeded with rabbit chondrocytes, which within days expressed the master chondrogenic transcription factor SOX9 and, by two weeks, began producing aggrecan and type II collagen, the hallmark molecules of cartilage matrix. Each scaffold was then wrapped in a cell sheet, fibroblast layer inward, EPC layer outward, and implanted under the skin of nude mice, whose lack of mature T cells allowed the researchers to isolate innate immune responses in a deliberately hostile, vascularized, connective-tissue-rich environment.

The protective results were striking. After fourteen days, unwrapped cell-free scaffolds were riddled with host cells, and their polymer structure showed partial degradation. Wrapped scaffolds, by contrast, showed dramatically reduced infiltration, with quantified hematoxylin-positive and DAPI-positive areas significantly lower than in the unwrapped controls, and their structural integrity was largely preserved. Immunostaining told a similar immunological story: CD45-positive leukocytes and F4/80-positive macrophages, abundant throughout unwrapped scaffolds, were markedly reduced in the wrapped ones. Type I collagen staining revealed a discontinuous boundary-like pattern at the periphery of wrapped scaffolds, suggesting the cell sheet persisted, at least partially, as a transient interface between implant and host.

Yet protection came at a price. When the researchers examined chondrocyte-laden scaffolds, they found that fibroblast-only wrapping sharply reduced cartilage matrix deposition. Safranin O and Alcian blue staining, which highlight the sulfated proteoglycans of cartilage, were markedly diminished in wrapped scaffolds compared with unwrapped controls. The most likely explanation, the authors suggest, is diffusion limitation: the dense cellular barrier that kept host cells out may also have throttled the transport of oxygen and nutrients into the scaffold interior, starving the chondrocytes of the metabolic support they need to build matrix. This mirrors a well-known problem in other encapsulation contexts, from islet transplantation, where semipermeable membranes can protect grafts while limiting their survival, to myocardial tissue engineering, where stacked cell sheets become hypoxic without adequate vascular integration.

This is where the EPCs earned their place. In scaffolds wrapped with the EPC-incorporated sheet, cartilage matrix deposition was restored to levels comparable with unwrapped controls, with robust Safranin O and Alcian blue staining throughout the construct. Critically, the vascular benefit was spatially controlled. CD31 immunostaining revealed that EPC-containing scaffolds developed significantly more CD31-positive vascular structures in the peri-scaffold region, the roughly 200-micrometer zone surrounding the implant, while the scaffold interior showed no significant increase in vascularization compared with the other groups. In other words, the engineered interface created a vascularized sleeve around the cartilage—much like the perichondrium and subchondral bone do in native tissue—without letting vessels invade and disrupt the cartilage itself, a balance that excessive vascular ingrowth is known to upset.

The team also tested simpler alternatives, and the comparison proved instructive. A porous polycarbonate membrane seeded with fibroblasts and EPCs kept host cells out entirely, but cartilage-like tissue formed only near the scaffold boundary, leaving the interior sparse and matrix-poor—a reminder that a rigid physical barrier can be too effective, sealing the scaffold off from the very interactions it needs. A GelMA hydrogel encapsulation, meanwhile, largely degraded within the two-week implantation window, allowing extensive heterogeneous cellular infiltration and producing no cartilage-like tissue at all. The living cell sheet, by contrast, achieved something neither synthetic membrane nor hydrogel could: a cohesive, biologically integrated boundary that both shields and communicates, contacting the scaffold and host tissue directly while modulating what passes between them.

The implications reach well beyond the laboratory bench. Cartilage scaffolds implanted in joint defects benefit from regular mechanical loading and an avascular, relatively homogeneous environment, but constructs destined for tracheal repair or craniofacial reconstruction, such as treating microtia, face heterogeneous surroundings teeming with connective tissue, immune activity, and dynamic mechanical forces—conditions that have doomed many previous attempts. By demonstrating that a fibroblast-based cell sheet can act as a bioactive regulator of scaffold-host interactions, the study points toward a design principle: rather than engineering the scaffold alone, engineers the boundary. The authors acknowledge that their subcutaneous model does not fully replicate the mechanical and tissue-specific demands of orthotopic sites, that only male mice were used, and that future work should combine the approach with 3D-printed or electrospun scaffolds and test it in tracheal and auricular implantation models. But the core message is clear and potentially transformative: a living wrapper, borrowed from the body’s own anatomy, can protect an engineered implant, choreograph its vascular supply, and let cartilage grow—turning the hostile host environment from an adversary into a partner in regeneration.

Subject of Research: Bioactive fibroblast and endothelial progenitor cell sheet encapsulation for regulating scaffold-host interactions in cartilage tissue engineering

Article Title: A bioactive cell sheet interface regulates scaffold–host interactions for cartilage regeneration

Article References: Chang, Y. C., Chang, C.-S., & Tsao, C.-K. (2026). A bioactive cell sheet interface regulates scaffold–host interactions for cartilage regeneration. Bioengineering & Translational Medicine, Article e70177. https://doi.org/10.1002/btm2.70177

Image Credits: AI Generated

DOI: 10.1002/btm2.70177

Keywords: cartilage regeneration, cell sheet engineering, tissue engineering, fibroblasts, endothelial progenitor cells, PCL scaffold, vascularization, host immune response, tracheal repair, chondrocytes, extracellular matrix, biomaterials

The material at the heart of the study, published in the journal Angiogenesis, is a polymer built from 2-methacryloyloxyethyl phosphorylcholine, abbreviated MPC, whose side chains carry the same phosphorylcholine head group that decorates the outer leaflet of every human cell membrane. Phosphorylcholine-based polymers have a long and distinguished history in biomedical engineering precisely because of this biomimicry. They are zwitterionic, meaning they carry paired positive and negative charges that produce a strongly hydrated surface, which resists protein adsorption, platelet adhesion, and thrombus formation. That property has made MPC polymers the coating of choice for cardiovascular stents, contact lenses, and other blood-contacting medical devices. What the Montreal team, led by co-senior authors May Griffith and Bruno Larrivée, has done is to flip the script on this famously inert material: instead of exploiting phosphorylcholine chemistry to keep cells at arm’s length, they deploy nanoparticles of the polymer as an active biological stimulus that vessel cells willingly devour.

The nanoparticles themselves are formed from polyMPC, the polymerized form of the methacrylated monomer, and were engineered to fall below a critical size threshold of roughly 150 nanometers in diameter. That figure is not arbitrary. Work on size-dependent cellular uptake stretching back to classic studies of clathrin- and caveolae-mediated endocytosis has shown that particles in this range are internalized by cells far more efficiently than larger counterparts, which tend to remain at the surface or enter through less productive pathways. When the researchers exposed human umbilical vein endothelial cells, the workhorse HUVEC model of vascular biology, to these sub-150-nanometer particles, the cells readily swallowed them. Once inside, the nanoparticles did something remarkable: rather than sitting inertly in endosomes, they triggered a cascade of signaling events that pushed the endothelial cells into an actively angiogenic state.

Tracing that cascade led the team to protein kinase C, or PKC, a family of enzymes that sits at a major signaling crossroads in many cell types. Upon internalization of the polyMPC nanoparticles, PKC was recruited to the plasma membrane, the canonical step that converts the kinase from an inactive cytosolic form into its active, membrane-bound state. PKC activation in endothelial cells is tightly linked to the stimulation of endothelial nitric oxide synthase, which produces nitric oxide, a master regulator of vessel dilation, endothelial migration, and new vessel sprouting. The finding that a synthetic zwitterionic polymer can engage this pathway offers a mechanistic explanation for how a material long considered biologically quiet can, in nanoparticle form, become a potent pro-angiogenic agent. It also suggests that the cell membrane itself, or the membrane trafficking machinery that processes the internalized particles, may be the unexpected trigger that converts a physical delivery event into a biochemical signal.

The downstream consequences of this activation were mapped with RNA sequencing, an unbiased technique that captures the full transcriptional response of treated cells. The profiles of HUVECs exposed to polyMPC nanoparticles showed upregulation of pro-angiogenic growth factors, including VEGF and fibroblast growth factor 2 (FGF2), two of the most important drivers of blood vessel growth in both development and repair. In other words, the nanoparticles did not act as growth factors themselves; they acted upstream, flipping genetic switches inside endothelial cells so that the cells became factories for their own angiogenic signals. Functional assays confirmed the transcriptional story: treated endothelial cells proliferated more vigorously and mounted characteristic angiogenic responses in culture, forming the tube-like networks that are the in vitro hallmark of vessel-forming behavior.

Crucially, the pro-angiogenic effect was not confined to a single cell type. The researchers found that polyMPC nanoparticles also promoted the expansion of endothelial progenitor cells derived from human cord blood and bone marrow. These progenitors are the circulating seed cells that the body uses to repair and rebuild vasculature, and their mobilization and expansion are central goals of cell-based approaches to ischemic disease. A material that can simultaneously stimulate mature endothelial cells and support the growth of progenitor populations could therefore act on both arms of vascular regeneration, the local sprouting of new vessels from existing ones and the recruitment of the cellular precursors that seed new vascular networks.

To test whether the effect would survive the far messier environment of living tissue, the team implanted polyMPC nanoparticles inside Matrigel plugs under the skin of mice, a standard in vivo assay in which a basement-membrane extract serves as a neutral scaffold. Blood vessels from the surrounding host tissue grow into the plug only if something inside it attracts them, so the degree of vascularization provides a direct readout of pro-angiogenic activity. The polyMPC-laden plugs produced a significant angiogenic response, drawing in host vessels at levels that confirmed the cell culture results translated to a living organism. Equally important was a observation about persistence: the delivered nanoparticles could be retained in tissue for extended periods, which means a single implantation could provide a sustained stimulus rather than the brief pulse of activity that plagues injected protein therapeutics. Because the nanoparticles work by inducing the tissue’s own production of VEGF, FGF2, and other growth factors, the therapeutic signal is continuously renewed at the site where it is needed, in the correct proportions and in the natural context of the tissue microenvironment.

The clinical problem the researchers are aiming at is enormous. Ischemic vascular pathologies, including peripheral artery disease, critical limb ischemia, and myocardial infarction, affect hundreds of millions of people worldwide and are a leading cause of amputation and heart failure. Existing attempts at therapeutic angiogenesis have ranged from gene therapy delivering VEGF or hepatocyte growth factor genes to infusions of autologous stem cells, with mixed and often underwhelming results in controlled trials. Recombinant protein approaches face pharmacological hurdles: free growth factors have short half-lives, risk ectopic vessel growth and leaky, malformed vasculature, and are costly to produce in pharmaceutical grade. The polyMPC strategy sidesteps several of these objections at once. The particles are made from a polymer with an established safety record in approved medical devices, they are relatively inexpensive to synthesize compared with recombinant proteins or viral vectors, and their mechanism recruits the body’s own regulated programs of vessel growth rather than flooding tissue with a single supraphysiological factor.

There are also broader implications for the field of biomaterials science. Phosphorylcholine polymers have been celebrated for four decades as the archetypal non-fouling, non-activating surface chemistry, and their zwitterionic cousins are now being engineered into next-generation lipid nanoparticles for drug and RNA delivery, where their ability to modulate interactions with lipid rafts and membrane trafficking pathways is increasingly recognized. The Montreal study adds a new chapter to that story by showing that the same membrane-mimetic chemistry, presented in the right physical form and size range, can be an active participant in cell signaling rather than a passive bystander. The boundary between a biomaterial that hides from biology and one that directs biology may be thinner than the field has assumed, and size, presentation, and cell type all appear to determine which side of that boundary a given formulation occupies.

The work remains at the preclinical stage, and the path from subcutaneous Matrigel plugs in mice to treating a diabetic patient’s ischemic foot is long and demanding, requiring tests of dose, delivery route, long-term biocompatibility, and efficacy in models of true tissue ischemia. The authors have filed a provisional patent application through their hospital research centre, a signal that they see a translational pathway for the technology. Even at this early stage, the concept is striking: a cheap, stable, biocompatible polymer particle that quietly enters blood vessel cells, wakes up their internal growth programs, and leaves the tissue to heal itself with vessels built from its own blueprint. If that concept survives the gauntlet of preclinical and clinical testing, phosphorylcholine, one of the most familiar molecules in biomaterials science, may find its most consequential role not in coating devices, but in regrowing the vasculature that failing tissues so desperately need.

Subject of Research: Polymer nanoparticles that stimulate angiogenesis in ischemic tissue

Article Title: Angiogenesis-promoting properties of phosphorylcholine mimetic nanoparticles

Article References: Moradi, M., Poudel, B. K., Hooker, E., Aghajanzadeh-Kiyaseh, M., Rusu, D., Griffith, M., & Larrivée, B. (2026). Angiogenesis-promoting properties of phosphorylcholine mimetic nanoparticles. Angiogenesis, 29(4), Article 71. https://doi.org/10.1007/s10456-026-10094-0

Image Credits: AI Generated

DOI: 10.1007/s10456-026-10094-0

Keywords: angiogenesis, nanoparticles, polyMPC, phosphorylcholine, therapeutic angiogenesis, endothelial cells, protein kinase C, VEGF, FGF2, endothelial progenitor cells, RNA sequencing, ischemic disease

Vascular grafts are pivotal tools in treating occlusive vascular diseases, yet their long-term success hinges on rapid and complete endothelialization—the process by which endothelial cells line the inner surface of blood vessels. Traditional synthetic grafts suffer from thrombosis and intimal hyperplasia largely due to delayed or incomplete endothelial coverage. Previous efforts to enhance endothelialization focused mostly on modifying graft surface chemistries or pre-seeding with endothelial cells. Despite these interventions, clinical outcomes remain suboptimal, highlighting the need for a deeper understanding of in vivo cellular mechanisms that govern graft integration.

The study team employed cutting-edge bioprinting technologies to fabricate vascular grafts with precise architecture and biochemical properties conducive to cellular colonization. These constructs were engineered to mimic the extracellular matrix composition and mechanical stiffness characteristic of native vessels. Leveraging a sophisticated in vivo murine model, the researchers traced the recruitment and differentiation of circulating endothelial progenitors—immature cells capable of giving rise to mature endothelial cells—highlighting their crucial role in orchestrating graft lining.

What sets this work apart is the elucidation of the communication axis between the perivascular niche—the microenvironment adjacent to blood vessels rich in supporting cells and signaling molecules—and the circulating endothelial progenitors. Using advanced imaging techniques and single-cell transcriptomics, the team identified key paracrine signals and cellular adhesion cascades that facilitate progenitor homing, survival, and differentiation. This crosstalk accelerates the establishment of a functional endothelial monolayer, drastically reducing the window during which grafts are vulnerable to thrombosis.

A pivotal discovery was the identification of a feedback loop wherein endothelial progenitors not only respond to niche-derived signals but also modulate the microenvironment by secreting angiocrine factors. These factors enhance progenitor recruitment and prime the scaffold surface for optimal cell adhesion and proliferation. This dynamic reciprocity challenges the conventional view of vascular niches as passive reservoirs, painting them instead as active participants in vascular regeneration.

Importantly, the researchers leveraged transcriptomic profiling to decode the gene expression changes underpinning progenitor cell activation and differentiation. Key molecular players such as VEGF-A, CXCL12, and Notch signaling components were found to be instrumental in mediating progenitor-endothelial lineage commitment and integration. Modulating these pathways pharmacologically further boosted endothelialization rates, offering a potential therapeutic avenue to complement bioprinted graft implantation.

The integration of endothelial progenitors was validated by immunohistochemical analyses demonstrating the rapid formation of a contiguous and functional endothelial layer, marked by expression of mature endothelial markers such as PECAM-1 and VE-Cadherin. Functional assays confirmed restored barrier function and antithrombotic properties, highlighting the grafts’ biocompatibility and resilience. These findings signal a remarkable step forward in mitigating the complications traditionally associated with vascular implants.

Of particular note was the temporal profile of endothelialization. Where conventional grafts may require weeks or even months to acquire sufficient endothelial coverage, the bioprinted grafts in this study achieved comparable endothelialization within days. This rapid timeline is crucial in dictating clinical success, potentially reducing the need for anticoagulation therapy and minimizing early graft failure.

The research also underscores the significance of the perivascular niche, extending the concept of stem cell niches into the domain of vascular biology. This niche provides essential cues not only for progenitor recruitment but also for maintaining their stemness and guiding differentiation. Perturbing niche signals experimentally confirmed their indispensable role, paving the way for future bioengineering approaches that integrate niche components to enhance graft performance.

Moreover, this work bridges the gap between regenerative biology and biofabrication, demonstrating that the design of vascular grafts must transcend structural mimicry and incorporate biological cues that actively engage host progenitors. This biologically integrated design philosophy sets a new paradigm for future tissue-engineered vascular grafts and potentially other organ systems reliant on rapid cellular incorporation.

The translational potential of this research is immense. Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, with millions requiring vascular interventions annually. Synthetic and autologous grafts are limited by availability and compatibility issues. Bioprinted grafts that harness the body’s own regenerative capacities herald a new era of personalized vascular medicine, capable of overcoming these limitations and offering longer-lasting, more effective therapies.

While additional studies are needed to scale this approach to larger animal models and subsequently human trials, the mechanistic insights uncovered lay a solid foundation for therapeutic innovation. Future work may also explore combining this strategy with drug delivery systems to further modulate the vascular microenvironment, enhancing engraftment and long-term function.

In summary, the conjunction of bioengineered vascular scaffolds and the endogenous perivascular niche-derived progenitor population constitutes a powerful strategy to achieve rapid and functional endothelialization. This synergy leverages natural regenerative pathways, reducing reliance on exogenous cells and complex pre-conditioning protocols. As the field advances, such innovations could dramatically improve outcomes in cardiovascular surgery and pave the way for next-generation implantable devices.

The implications extend beyond vascular grafts, potentially informing regenerative strategies for all tissues reliant on organized endothelial structures, including organoids, engineered tissues, and synthetic organs. By deciphering and leveraging the cellular crosstalk governing vascular integration, Zhang, Yuan, Yao, and colleagues have opened a transformative frontier in regenerative medicine, combining the precision of additive manufacturing with the elegance of biological systems.

This pioneering work exemplifies the power of interdisciplinary collaboration, uniting materials science, stem cell biology, vascular physiology, and bioengineering. As we step further into an era where synthetic and biological components are seamlessly integrated, such studies underscore the limitless potential of designing implants that not only replace damaged tissues but also activate the body’s inherent capacity for healing and regeneration.

Subject of Research: Rapid endothelialization of 3D-printed vascular grafts through cellular crosstalk between perivascular niche and circulating endothelial progenitors.

Article Title: Rapid endothelialization of printed vascular grafts by perivascular niche-circulating endothelial progenitors crosstalk.

Article References: Zhang, Zq., Yuan, PP., Yao, C. et al. Rapid endothelialization of printed vascular grafts by perivascular niche-circulating endothelial progenitors crosstalk. Nat Commun (2025). https://doi.org/10.1038/s41467-025-68075-8

Image Credits: AI Generated